Navigation Links
Newly Published Case Series Demonstrates the Karius Test’s Effectiveness for Monitoring Infections in Stem-Cell Transplant Patients at Risk of Infections
Date:12/13/2018

Karius, Inc., a life sciences company transforming infectious disease diagnostics with genomics, announced today the results of an ongoing clinical study of adult patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The early findings showed that the Karius® Test, a non-invasive blood test that detects pathogen cell-free DNA in plasma, is an effective infectious disease diagnostic that can quickly and accurately detect infections early and potentially help guide therapy in these patients.

Allo-HSCT is a life-saving treatment for patients with high-risk leukemia. However, it increases the risk of infections, which can cause significant complications and death in this population [1]. Diagnosing infections in allo-HSCT patients is challenging due to their susceptibility to uncommon pathogens and atypical clinical presentations of disease. Current laboratory methods are also frequently unable to establish a clear diagnosis for an infection. [1,2]

Dr. Monica Fung, UCSF, first author of the study, says, “We often struggle to make a diagnosis in patients with stem cell transplants. Their infections don’t manifest with the typical symptoms you see in healthy individuals. What is exciting about the Karius Test is its ability to test a really broad range of pathogens quickly.”

The publication describes three unique cases that highlight the benefits of a novel, non-invasive, rapid diagnostic tool for the management of patients at high risk of infections. These patients are enrolled in the DISCOVER (Diagnosis of Infection in Stem Cell Transplant Patients OVER Time) study at UCSF. In these patients, the Karius Test had the potential to detect bacterial infections prior to initial symptoms or conventional tests.

Dr. Peter Chin-Hong and Dr. Aaron Logan from UCSF were lead authors of the study. Dr. Chin-Hong says: “The timing of a diagnosis for an infection in immunocompromised patients is very important, every minute matters. These findings show the utility of the test to quickly and accurately detect infections with a non-invasive method.”

One case showed that the Karius Test detected Chlamydia trachomatis 7 days prior to initial symptoms and 30 days prior to standard microbiologic diagnosis. In another case, the Karius Test detected Staphylococcus aureus even after the patient had been on antibiotics and before conventional microbiology tests identified an infection. These findings suggest the potential value of the Karius Test to help guide therapy and monitor treatment to help improve outcomes.

“This first look at the results from the DISCOVER trial shows the promise of the Karius Test in identifying pathogens in stem-cell transplant patients prior to conventional microbiology tests. This could lead to earlier targeted treatment in these high-risk patients,” says Dr. David Hong, VP of Medical Affairs and Clinical Development at Karius.

The study is available on the Open Forum Infectious Diseases Journal’s website at https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofy301/5184895

1.    Wingard JR, Hsu J, Hiemenz JW. Hematopoietic Stem Cell Transplantation: An Overview of infection risks and epidemiology.
2.    Serody JS, Berrey MM, Albritton K, et al. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant, 2000; 26: 533-8.

About Karius, Inc.
Karius is a life sciences company focused on transforming infectious disease diagnostics with genomics and data through the innovative use of next-generation sequencing to analyze microbial cell-free DNA. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing. The company’s genomics platform and clinically-curated pathogen database deliver deep insight into the microbial landscape, providing clinicians with a comprehensive, quantitative test capable of identifying more than a thousand pathogens directly from blood and helping industry accelerate drug development. For more information, visit kariusdx.com and follow us on Twitter at @kariusdx.

Read the full story at https://www.prweb.com/releases/newly_published_case_series_demonstrates_the_karius_tests_effectiveness_for_monitoring_infections_in_stem_cell_transplant_patients_at_risk_of_infections/prweb15983820.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Upsher-Smith Introduces Newly Redesigned Corporate Website
2. Worldwide Orthopaedic Product Sales Reached $43.1 Billion in 2012, States ORTHOWORLDs Newly-released Orthopaedic Industry Report
3. Ferring Pharmaceuticals Inc. Announces $1M Donation to the Alliance for Fertility Preservation, a Newly Formed Charitable Organization
4. aTyr Pharma Completes $49 Million Financing to Advance a Therapeutic Pipeline for Rare Autoimmune Diseases from a Newly Discovered Class of Proteins, Physiocrines
5. Arthritis in Dogs is Now Treatable with a Newly-Released High Quality Supplement from Pear & Berry
6. Newly-Published Study Concludes Stretta May Be More Desirable GERD Treatment than Chronic PPI Use or Anti-Reflux Surgery in Some Patients
7. Medbox Focuses on Newly Emerging Medical and Recreational Marijuana States
8. EMD Serono Exclusive Supporter of Newly Launched Multiple Sclerosis Resource Centre
9. Medbox Targets Newly Emerging $1.3 Billion Canadian Medical Marijuana Market
10. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
11. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2019)... ... March 15, 2019 , ... Dallas plastic surgeon, Dr. ... best plastic surgeons in the country by Castle Connolly's Top Doctor program. Every ... professionals in acknowledged medical specialties such as plastic surgery, carefully screens and selects ...
(Date:3/14/2019)... WARNER ROBINS, Ga. (PRWEB) , ... March 14, ... ... small minority-owned business enterprise (MBE) LOUi Consulting Group, Inc. (LCGI) its fourth consecutive ... DHA has awarded LCGI a $7M, 22-month contract to maintain the computer servers ...
(Date:3/14/2019)... , ... March 14, 2019 , ... The eVox® ... assess brain function in-office and use the results to aid in making a clinical ... to announce our distribution partnership with Thought Technology which will expand access to the ...
Breaking Medicine Technology:
(Date:3/15/2019)... ... , ... The National Association of Chain Drug Stores (NACDS) praises the enactment ... through Schedule VI, which will help prevent opioid abuse. Arkansas Gov. Asa Hutchinson (R) ... , NACDS recognizes the leadership of State Sen. Kim Hammer (R), sponsor ...
(Date:3/15/2019)... ... , ... One of the leading causes of infertility in women of reproductive ... characterized as confusing and enigmatic, Shady Grove Fertility, a national leader in infertility and ... on March 19, 2019 with Dr. Naveed Khan of SGF’s Leesburg, ...
(Date:3/14/2019)... ... March 14, 2019 , ... Reset Summer Camp, one of the only summer ... the opening of their application portal for summer 2019. In addition, the ... Dr. Deborah Gilboa – popularly known as Dr. G – to oversee family ...
(Date:3/14/2019)... ... ... Cell & Gene Therapy Strategies for Successful BLA Submissions, Best Practices for ... - 3:00 p.m. EDT, http://www.fdanews.com/blasubmissions , The FDA predicts that by 2025 ... , That will only come true if sponsors are ready for the unique ...
(Date:3/12/2019)... ... March 12, 2019 , ... ... events, AdventHealth care teams will provide comprehensive, on-site services at the exclusive Midway ... by Advanced Auto Parts. The Infield Care Center will be staffed with emergency ...
Breaking Medicine News(10 mins):